Ipilimumab, a therapy targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), was well tolerated but demonstrated little effectiveness, though it is FDA approved for the treatment of unresectable childhood melanoma [384,386]. This evidence concerns the gene CTLA4 and melanoma.